Aridis Pharmaceuticals, Inc.

ARDSOTCHealthcare● Active

$0.00

+$0.00(+0.00%)

Market Cap$8915

P/E Ratio—

52W High$0.05

52W Low$0.0001

Avg Volume6K

Open$0.00

Beta-26.04

Overview

Aridis Pharmaceuticals, Inc. (ARDS) Earnings: Dates, EPS & Revenue History

Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.

ARDS · earnings · updated Jun 8, 2026

Latest Earnings

Q4 FY2023Report Date: Nov 6, 2023

EPS Actual

-$0.02

Est. -$0.10 · +80.0%

Revenue

$0.00B

Est. $0.00B · +39.0%

Fiscal Period

Q4 FY2023

FY ends December

Report Date

Nov 6, 2023

After Market Close

▲ Beat EPS▲ Beat Revenue✓ 1-Quarter EPS Beat Streak

ARDS reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.

Next Earnings Date

Days Away

days

Expected Date

Sep 1, 2026

Fiscal Period

Q3 FY2026

Release Time

◌ Time TBD (Unconfirmed)

EPS Est.

$0.21

Rev. $0.66B

Days Away85

Expected DateSep 1, 2026

Fiscal PeriodQ3 FY2026

Release TimeTime TBD (Unconfirmed)

EPS Est.$0.21

Rev. Est.$0.66B

EPS & Revenue vs. Estimates

Actual (Beat)

Actual (Miss)

Estimated

Earnings History

Period	Report Date	EPS Est.	EPS Actual	EPS Surpr.	Revenue	Rev. Est.	Rev. Surpr.
◌ Q2 FY2026	Jun 12, 2026	—	—	—	—	—	—
◌ Q2 FY2026	Jun 12, 2026	-$0.63	—	—	—	$0.00B	—
◌ Q1 FY2026	Feb 25, 2026	-$0.60	—	—	—	$0.00B	—
◌ Q2 FY2025	Jun 4, 2025	—	—	—	—	—	—
◌ Q2 FY2025	May 29, 2025	—	—	—	—	—	—
◌ Q1 FY2025	Mar 28, 2025	—	—	—	—	—	—
◌ Q4 FY2024	Nov 18, 2024	—	—	—	—	—	—
◌ Q3 FY2024	Sep 27, 2024	—	—	—	—	$0.00B	—

Q2 FY2026

Jun 12, 2026

EPS Actual

—

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q2 FY2026

Jun 12, 2026

EPS Actual

—

EPS Est.

-$0.63

EPS Surpr.

—

Revenue

—

Q1 FY2026

Feb 25, 2026

EPS Actual

—

EPS Est.

-$0.60

EPS Surpr.

—

Revenue

—

Q2 FY2025

Jun 4, 2025

EPS Actual

—

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q2 FY2025

May 29, 2025

EPS Actual

—

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q1 FY2025

Mar 28, 2025

EPS Actual

—

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q4 FY2024

Nov 18, 2024

EPS Actual

—

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q3 FY2024

Sep 27, 2024

EPS Actual

—

EPS Est.

—

EPS Surpr.

—

Revenue

—

Analyst Estimates

Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.

EPS Estimates

Period	Low	Consensus	High	# Analysts
Q3 FY2029	$-0.02	$-0.02	$-0.02	1
Q2 FY2029	$-0.10	$-0.10	$-0.10	1
Q1 FY2029	$-0.10	$-0.10	$-0.10	1
Q4 FY2028	$-0.02	$-0.02	$-0.02	1
Q3 FY2028	$-0.10	$-0.10	$-0.10	1
Q2 FY2028	$-0.10	$-0.10	$-0.10	1

Revenue Estimates

Period	Low	Consensus	High	# Analysts
Q3 FY2029	$0.0B	$0.0B	$0.0B	1
Q2 FY2029	$0.0B	$0.0B	$0.0B	1
Q1 FY2029	$0.0B	$0.0B	$0.0B	1
Q4 FY2028	$0.0B	$0.0B	$0.0B	1
Q3 FY2028	$0.0B	$0.0B	$0.0B	1
Q2 FY2028	$0.0B	$0.0B	$0.0B	1

Earnings Price Reaction

Closing price one trading day before vs. one trading day after each earnings release.

Period	Report Date	EPS Beat/Miss	Price Before	Price After	1D Reaction
▲ Q4 FY2023	Nov 6, 2023	+80.0%	$0.09	$0.08	-13.51%
— Q3 FY2023	Sep 13, 2023	—	$0.08	$0.07	-12.67%
— Q2 FY2023	May 22, 2023	—	$0.20	$0.22	+10.10%

Q4 FY2023-13.51%

Report Date

Nov 6, 2023

EPS Beat/Miss

+80.0%

Price Before

$0.09

Price After

$0.08

Q3 FY2023-12.67%

Report Date

Sep 13, 2023

EPS Beat/Miss

—

Price Before

$0.08

Price After

$0.07

Q2 FY2023+10.10%

Report Date

May 22, 2023

EPS Beat/Miss

—

Price Before

$0.20

Price After

$0.22

Avg Beat Reaction-13.51%

Beat Rate1 / 3 quarters

Largest Move-13.51% (Q4 FY2023)

Data: FMP /historical-price-eod/full · field: close

About Earnings & Data Methodology

Aridis Pharmaceuticals, Inc. (ARDS) most recently reported earnings on November 6, 2023 for Q4 FY2023, posting EPS of $-0.02 — beating the analyst consensus of $-0.10 by +80.0%. The next ARDS earnings date is expected around September 1, 2026.

Each quarter, investors track ARDS earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ARDS revenue tab →

Earnings Glossary

EPS (Earnings Per Share)

Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.

Earnings Surprise %

(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.

Beat / Miss / In-Line

Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.

BMO / AMC

Before Market Open / After Market Close. Two windows when companies typically release results.

Fiscal Quarter

ARDS's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.

Analyst Consensus

Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.

Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.

Revenue Price history Financial statements Forecast Dividends Market cap

Frequently asked questions

ARDS earnings · 5 questions

Aridis Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. ARDS typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ARDS historically reports after market close (AMC).

ARDS earnings datewhen is ARDS earningsARDS next earnings datewhen does ARDS report earningsARDS earnings calendar

▸ Source: FMP · Aridis Pharmaceuticals, Inc. SEC filings · US GAAP · Aridis Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026